Literature DB >> 18327480

Comparison between E-test and CLSI broth microdilution method for antifungal susceptibility testing of Candida albicans oral isolates.

Cristiane Yumi Koga-Ito1, Juliana Pereira Lyon, Maria Aparecida de Resende.   

Abstract

Thirty Candida albicans isolated from oral candidosis patients and 30 C. albicans isolated from control individuals were studied. In vitro susceptibility tests were performed for amphotericin B, fluconazole, 5-flucytosine and itraconazole through the Clinical and Laboratorial Standards Institute (CLSI) reference method and E test system. The results obtained were analyzed and compared. MIC values were similar for the strains isolated from oral candidosis patients and control individuals. The agreement rate for the two methods was 66.67% for amphotericin B, 53.33% for fluconazole, 65% for flucytosine and 45% for itraconazole. According to our data, E test method could be an alternative to trial routine susceptibility testing due to its simplicity. However, it can not be considered a substitute for the CLSI reference method.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18327480     DOI: 10.1590/s0036-46652008000100002

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


  7 in total

1.  The association between fluconazole dose and MIC with mortality and persistence in candidemia.

Authors:  Nesrin Ghanem-Zoubi; Majd Qasum; Johad Khoury; Danny Zorbavel; Merav Arnon; Yuval Geffen; Mical Paul
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-06-13       Impact factor: 3.267

2.  Comparison of Disc Diffusion, Etest, and a Modified CLSI Broth Microdilution Method for In Vitro Susceptibility Testing of Itraconazole, Posaconazole, and Voriconazole against Madurella mycetomatis.

Authors:  Bertrand Nyuykonge; Lukas van Amelsvoort; Kimberly Eadie; Ahmed H Fahal; Annelies Verbon; Wendy van de Sande
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

3.  Antifungal Activity of Novel Formulations Based on Terpenoid Prodrugs against C. albicans in a Mouse Model.

Authors:  Suvidha Menon; Xiuyi Liang; Richa Vartak; Ketankumar Patel; Antonio Di Stefano; Ivana Cacciatore; Lisa Marinelli; Blase Billack
Journal:  Pharmaceutics       Date:  2021-04-29       Impact factor: 6.321

4.  Antifungal Susceptibility Testing with Etest for Candida Species Isolated from Patients with Oral Candidiasis.

Authors:  You Bum Song; Moo Kyu Suh; Gyoung Yim Ha; Heesoo Kim
Journal:  Ann Dermatol       Date:  2015-12-07       Impact factor: 1.444

5.  A chromosome 4 trisomy contributes to increased fluconazole resistance in a clinical isolate of Candida albicans.

Authors:  Matthew Z Anderson; Amrita Saha; Abid Haseeb; Richard J Bennett
Journal:  Microbiology       Date:  2017-06-22       Impact factor: 2.777

6.  In Vitro Antifungal Susceptibility of Candida Species Isolated from Iranian Patients with Denture Stomatitis.

Authors:  Saeid Mahdavi Omran; Maryam Rezaei Dastjerdi; Maryam Zuashkiani; Vahid Moqarabzadeh; Mojtaba Taghizadeh-Armaki
Journal:  Biomed Res Int       Date:  2018-05-16       Impact factor: 3.411

7.  Susceptibility tests of oropharyngeal Candida albicans from egyptian patients to fluconazole determined by three methods.

Authors:  Noha El-Mashad; Mona F Foad; Niveen Saudy; Dalia A Salem
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.